Atara Biotherapeutics
ATRA
76 hedge funds and large institutions have $479M invested in Atara Biotherapeutics in 2016 Q3 according to their latest regulatory filings, with 9 funds opening new positions, 29 increasing their positions, 21 reducing their positions, and 7 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
38% more repeat investments, than reductions
Existing positions increased: 29 | Existing positions reduced: 21
29% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 7
3% more funds holding
Funds holding: 74 → 76 (+2)
3% less capital invested
Capital invested by funds: $493M → $479M (-$13.7M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$8.88M |
| 2 |
Alyeska Investment Group
Chicago,
Illinois
|
+$8.8M |
| 3 |
AG
Artal Group
Luxembourg
|
+$4.89M |
| 4 |
Norges Bank
Oslo,
Norway
|
+$1.85M |
| 5 |
ACH
ArrowMark Colorado Holdings
Denver,
Colorado
|
+$1.46M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RG
Redmile Group
San Francisco,
California
|
-$8.41M |
| 2 |
UBS AM
Chicago,
Illinois
|
-$6.51M |
| 3 |
TAM
Tiverton Asset Management
Wilimington,
Delaware
|
-$2.68M |
| 4 |
JP Morgan Chase
New York
|
-$2.03M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$602K |
ATRA Hedge Fund Activity: Q3 2016 in Review
76 of the 3,759 institutional investors tracked by Wall St. Rank reported a position in Atara Biotherapeutics (ATRA) for Q3 2016, worth a combined $479M — down 2.8% from $493M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new ATRA positions and 7 closed out — a net gain of 2 holders — while 29 added to existing stakes and 21 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $8.88M. The largest seller was Redmile Group, cutting an estimated $8.41M.
- 76 institutional investors held Atara Biotherapeutics (ATRA) as of Q3 2016, up from 74 in Q2 2016.
- Funds reported $479M of Atara Biotherapeutics stock for Q3 2016, down 2.8% quarter-over-quarter.
- 9 funds opened new Atara Biotherapeutics positions in Q3 2016 and 7 closed out, a net change of +2 holders.
- The largest Atara Biotherapeutics buyer in Q3 2016 was Fidelity Investments, an estimated $8.88M added.
- The largest Atara Biotherapeutics seller in Q3 2016 was Redmile Group, an estimated $8.41M sold.
Based on aggregated 13F filings for Q3 2016.